近日，長春長生問題疫苗事件持續(xù)發(fā)酵，引爆輿論。7月22日，李克強(qiáng)總理就疫苗事件作出批示：此次疫苗事件突破人的道德底線，必須給全國人民一個明明白白的交代。
事已至此，唯有公開透明的處理方式，才能有效化解“問題疫苗”引發(fā)的公共衛(wèi)生危機(jī)。
李克強(qiáng)總理就疫苗事件作出批示
Premier Li Keqiang said in an instruction that the vaccine case has crossed a moral line, and the nation deserves a clear explanation, the State Council said on its website on Sunday.
國務(wù)院官網(wǎng)22日發(fā)布消息稱，李克強(qiáng)總理就疫苗事件作出批示：此次疫苗事件突破人的道德底線，必須給全國人民一個明明白白的交代。
▲資料圖（來源：中國政府網(wǎng)）
The State Council should immediately send a group to investigate to uncover the truth as soon as possible, and any wrongdoing will be severely punished regardless of who is involved, Li said.
李克強(qiáng)在批示中要求，國務(wù)院要立刻派出調(diào)查組，對所有疫苗生產(chǎn)、銷售等全流程全鏈條進(jìn)行徹查，盡快查清事實真相，不論涉及到哪些企業(yè)、哪些人都堅決嚴(yán)懲不貸、絕不姑息。
國家藥監(jiān)局：立案調(diào)查
The State Drug Administration has launched an investigation of Changchun Chang-sheng Bio-tech Co, which was found to have fabricated production records for freeze-dried rabies vaccines for human use.
國家藥品監(jiān)督管理局對長春長生生物科技有限責(zé)任公司開展調(diào)查，發(fā)現(xiàn)該企業(yè)凍干人用狂犬病疫苗生產(chǎn)存在記錄造假。
▲接受調(diào)查的長春長生生物科技有限公司生產(chǎn)的狂犬疫苗（圖片來源：CGTN）
The cases of those suspected of violating laws will be transferred to public security departments, the authority said on Sunday.
7月22日，藥監(jiān)局表示，涉嫌犯罪的將移送公安機(jī)關(guān)。
Xu Jinghe, deputy head of the drug administration, said the company was found to have fabricated production and inspection records.
國家藥品監(jiān)督管理局副局長徐景和表示，現(xiàn)已查明，企業(yè)編造生產(chǎn)記錄和產(chǎn)品檢驗記錄。
Such activities are in violation of the country’s drug management law and related regulations on drug production, Xu said.
這些行為嚴(yán)重違法了《中華人民共和國藥品管理法》，徐景和說。
In a notification on July 15, the drug administration ordered the company to stop producing the human rabies vaccine. It said no products involved in the inspection were currently being sold and all the vaccine involved had been removed.
國家藥品監(jiān)督局在15日的通告中責(zé)令該企業(yè)停止狂犬疫苗的生產(chǎn)。本次檢查所有涉事批次產(chǎn)品尚未出廠和上市銷售，全部產(chǎn)品已得到有效控制。
▲藥監(jiān)局對長春長生公司生產(chǎn)狂犬疫苗的調(diào)查通告（圖片來源：CGTN）
The administration has also revoked the company’s certificate that is needed for production and sales of the vaccine.
藥監(jiān)局還回收了該企業(yè)用于生產(chǎn)和銷售疫苗的證書。
除了狂犬疫苗，該公司生產(chǎn)的百白破疫苗也被曝出問題↓
Its remarks came amid public concerns about vaccine safety in China over the weekend, after it was also revealed that Changsheng Bio-tech was linked to a substandard adsorbed diphtheria-pertussis-tetanus, or ADPT, vaccine for infants.
上周末，隨著長春長生公司再度被曝所生產(chǎn)的嬰幼兒吸附無細(xì)胞百白破聯(lián)合疫苗不符合規(guī)定，中國公眾對疫苗安全表示擔(dān)憂。
On Friday, the Jilin Provincial Drug Administration announced a penalty regarding Changchun Changsheng Bio-tech Co's substandard ADPT vaccine.
7月20日，吉林省食品藥品監(jiān)督局公布了對長春長生生物科技有限責(zé)任公司因生產(chǎn)吸附無細(xì)胞百白破聯(lián)合疫苗不合規(guī)而進(jìn)行的處罰。
The company was fined 2.58 million yuan ($282,000), and 859,000 yuan in assets from sales of the vaccine were confiscated.
該企業(yè)被處以罰金258萬元，沒收違法所得85.9萬元。
The case was under investigation last year.
這起案件于去年接受調(diào)查。
Changsheng Bio-tech Co, parent company of Changchun Changsheng Bio-tech Co, revealed in November that 252,600 doses of the substandard ADPT vaccine that couldn't meet the standard of immunity results were all sold to Shandong province and had been recalled.
去年11月，長春長生科技有限責(zé)任公司的母公司——長生生物科技股份有限公司被曝銷往山東省的不合格百白破疫苗共計 252600 支，這些疫苗不符合免疫效果的標(biāo)準(zhǔn)，已要求召回。
“The substandard ADPT vaccine won’t post safety threats to people’s health, but will reduce the expected immune effects,” Dingxiang-yuan, a professional medical website, said in an online reply to public concerns about the vaccine’s safety.
“該批次百白破疫苗效價指標(biāo)不合格，可能影響免疫保護(hù)效果，但對人體安全性沒有影響�！倍∠銏@專業(yè)醫(yī)藥網(wǎng)對于公眾對疫苗安全的擔(dān)憂回復(fù)道。
The state drug administration confirmed on Sunday that it was discovered in October that one batch of Changsheng’s ADPT vaccine was substandard, and its production of ADPT has been suspended since then.
7月22日，藥監(jiān)局證實去年10月發(fā)現(xiàn)長生公司生產(chǎn)的某批次吸附無細(xì)胞百白破聯(lián)合疫苗不符合規(guī)定，此后這種疫苗停產(chǎn)。
A plan for reinoculation of those affected was worked out in February.
有關(guān)補(bǔ)種工作已于今年2月進(jìn)行了部署。
長生生物回應(yīng)：十分自責(zé)和愧疚
The Shenzhen Stock Exchange announced that it sent letters to Changsheng Bio-tech Co on Sunday, calling for early disclosure of the two cases to the public.
深圳證券交易所22日稱，已向長生生物科技股份有限公司發(fā)出關(guān)注函，要求其盡早向公眾披露兩起案件的信息。
“We will maintain strict supervision over the listed company’s information disclosure responsibility according to the law and guarantee legal rights of investors,” it said in the online announcement.
深交所在線上公告中指出，將依法全面從嚴(yán)監(jiān)管上市公司信息披露行為，切實保護(hù)投資者合法權(quán)益。
The Shenzhen Stock Exchange posted a reply from Changsheng Bio-tech Co later in the afternoon on its website. It says, “We feel very remorseful and guilty about what has happened, and we apologize to all those vaccinated and investors.”
深交所于當(dāng)日晚間發(fā)布了長生生物科技公司的回復(fù)，其中提到：“我們感到十分的自責(zé)和愧疚，再次向各位接種者和投資者表示深深的歉意。”
The company added that it will learn a lesson.
該企業(yè)還表示將引以為戒。
長生生物官網(wǎng)被黑：不搞你，對不起祖國的花朵
7月23日，長生生物官網(wǎng)首頁被黑客攻擊，并配圖“不搞你，對不起祖國的花朵”。
多方呼吁嚴(yán)懲，期待公開透明的處理方式
Several state media called for severe punishment and stricter supervision of vaccines. People’s Daily released a commentary on Sunday saying that drugmakers should stick to moral principles and make life their priority rather than profits.
多家官媒呼吁嚴(yán)懲疫苗問題，加強(qiáng)疫苗監(jiān)管�！度嗣袢請蟆�22日發(fā)表評論文章稱，制藥企業(yè)必須守住起碼的道德底線，必須以“敬畏生命”為信條。
The authorities need to release whatever information they know about the incident to the public as soon as possible.
事已至此，唯有公開透明的處理方式，才能有效化解“問題疫苗”引發(fā)的公共衛(wèi)生危機(jī)。
It is not just to pacify the public in the wake of this particular incident. It is also for a thorough overhaul of the industry as vaccines are directly related to people’s health, particularly children.
這不僅是為了平息輿論，更是為了整頓整個疫苗行業(yè)。畢竟這一行業(yè)關(guān)系著全國人民的生命健康，尤其牽涉著少年兒童，牽涉著祖國的未來。
